J&J petitions FDA to require "similar" names for biosimilars, biologics

09-01-2014 ReutersComments (0)

BiosimilarsJohnson & Johnson

J&J's view on naming of biosimilars contrasts that of Mylan Inc and Novartis AG over the past few months, as the U.S. Food and Drug Administration continues to work on drafting regulations for the approval of biosimilars -- cheaper versions of ...

Read more on Reuters

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top